| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Blinatumomab |
| Brand | Blincyto® |
| Indication | As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1%. |
| Assessment Process | |
| Rapid review commissioned | 19/08/2019 |
| Rapid review completed | 23/09/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price.* |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations February 2021.
